Sillajen announced that three research studies on its investigational anticancer drug BAL0891 have been selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025. The meeting is scheduled to take place from April 25 to 30 in Chicago, Illinois, U.S.
BAL0891 is currently undergoing phase 1 clinical trials in the U.S. and Korea, targeting patients with solid tumors. The drug has recently been involved in combination studies with Tevimbra (tislelizumab), an anti-PD-1 immune checkpoint inhibitor provided by BeiGene.
- First Study: Demonstrates that BAL0891 disrupts the cancer cell cycle, activating the cGAS/STING pathway. This activation promotes cytokine secretion, recruiting immune cells and enhancing the efficacy of immune checkpoint inhibitors, supporting the use of BAL0891 in combination with immune therapies for a stronger anticancer effect.
- Second Study: Utilizes a vascularized 3D tumor microenvironment model to evaluate BAL0891’s anticancer efficacy, reaffirming the drug’s synergy with immune checkpoint inhibitors. The model shows BAL0891 promotes tumor cell death, increases immune cell infiltration, and amplifies combination therapy effects.
- Third Study: Explores BAL0891’s responsiveness in patient-derived organoid (PDO) models, identifying potential biomarkers for predicting patient sensitivity to the drug.
Sillajen, in collaboration with Qureator, a San Diego-based biotechnology company specializing in 3D organoid research, has made significant strides in demonstrating BAL0891's superior anticancer effects and its combination efficacy with immune checkpoint inhibitors. Sillajen is committed to continuing its efforts to provide effective and innovative treatment options for cancer patients through ongoing BAL0891 clinical studies.
